Re: Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis

Wallis CJ¹, Saskin R², Choo R³, Herschorn S⁴, Kodama RT⁴, Satkunasivam R⁴, Shah PS⁵, Danjoux C⁶, Nam RK⁷

¹Division of Urology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada; Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.

²University of Toronto Faculty of Medicine, Institute of Health Policy, Division Management and Evaluation, Toronto, Canada; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Clinic of Urology, Toronto, Canada

³Mayo Clinic, Clinic of Radiation Oncology, Rochester, USA

⁴Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Clinic of Urology, Toronto, Canada; University of Toronto Faculty of Medicine, Department of Surgery, Clinic of Urology, Toronto, Canada

⁵University of Toronto Faculty of Medicine, Institute of Health Policy, Division Management and Evaluation, Toronto, Canada; Mount Sinai Hospital, Clinic of Pediatrics, Toronto, Canada; University of Toronto Faculty of Medicine, Department of Pediatrics, Toronto, Canada

⁶University of Toronto Faculty of Medicine, Department of Radiation Oncology, Toronto, Canada

⁷Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Clinic of Urology, Toronto, Canada; University of Toronto Faculty of Medicine, Department of Surgery, Clinic of Urology, Toronto, Canada; University of Toronto Faculty of Medicine, Institute of Health Policy, Division Management and Evaluation, Toronto, Canada


EDITORIAL COMMENT

Radical treatment options for patients with clinically-localized prostate cancer include radical prostatectomy and radiotherapy. Since there is no level 1 evidence comparing the efficacy of these two modalities, Wallis and coworkers conducted a systematic review and meta-analysis to compare the data on overall and prostate cancer-specific survival among patients treated with radiotherapy or radical prostatectomy for clinically-localized prostate cancer. Nineteen studies were selected and up to 118,830 patients were pooled. Of note, only two studies provided “dose-escalated” external beam radiotherapy treatments to all radiotherapy patients. The risk of overall (10 studies, aHR 1.63, 95% confidence interval 1.54–1.73, p < 0.00001; I²=0%) and prostate cancer-specific (15 studies, aHR 2.08, 95% confidence interval 1.76–2.47, p < 0.00001; I²=48%) mortality were higher for patients treated with radiotherapy compared with those treated with surgery. Subgroup analyses by risk group, radiation regimen, time period, and follow-up length did not alter the direction of results. They concluded that radiotherapy for prostate cancer is associated with an increased risk of overall and prostate cancer-specific mortality compared with surgery based on observational data. The methodological limitations of observational studies should be considered while interpreting the results. The ProtecT trial and SPCG-15 trial comparing radical prostatectomy to radiotherapy among patients with low/intermediate and high-risk cancer respectively are awaited.

Özgür Yaycioğlu, MD